Key result
Current evidence is insufficient to link inotrope use, specifically dobutamine and milrinone, to increased mortality in patients with low output heart failure.
Why the study?
Do inotropes increase mortality in patients with advanced heart failure?
Do inotropes increase mortality in patients with advanced heart failure?
This review challenges the common perception that inotropes inherently increase mortality in advanced heart failure, highlighting that current evidence is insufficient to support this view in patients with low output heart failure.
No takes yet. Share an insight, caveat, or question.
Does not justify avoiding inotropes over mortality concerns in low-output HF; leaves open need for prospective RCTs.
Maya Guglin (2014) conducted a review in Advanced heart failure. Inotropes (dobutamine and milrinone) was evaluated on Mortality. Current evidence is insufficient to link inotrope use, specifically dobutamine and milrinone, to increased mortality in patients with low output heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: